Consumers Health Forum worried on biosimilars


white pills and tablets: GMiA

The Consumers Health Forum has expressed its concerns about the issue of substitution of biological medicines with biosimilars, at a meeting called by the Pharmaceutical Benefits Advisory Committee.

CEO of the Forum, Leanne Wells, says that at the meeting there was “a consistency in the concern and opposition from clinical and consumer groups concerning the ‘a’ flagging of biosimilars and substituting them at the pharmacy level”.

“There was also consistency in the view that decisions to substitute should only be made in the context of the therapeutic doctor-patient relationship,” she says.

“We await with interest the response from the PBAC.

“This is a really complex, evolving area of medicine and underlines the need for clinicians, dispensers and patients to have access to independent and authoritative information.”

Previous Clinical tips: hepatitis C explained
Next Deakin Uni professor busts the biggest diabetes myths

NOTICE: It can sometimes take awhile for comment submissions to go through, please be patient.

2 Comments

  1. Sean T
    11/07/2015

    A concern based on what? Rigorous studies showing equivalency between the extortionately expensive originator drug and the substantially less expensive biosimilar? Or is the concern based on payment received by the originator drug’s manufacturer to pretend the rigorous studies showing equivalency don’t exist?

    • Jarrod McMaugh
      16/07/2015

      I think this is a valid point. It’s interesting to note who the members of the CHF include.

      CHF does have one thing right – “This is a really complex, evolving area of medicine and underlines the
      need for clinicians, dispensers and patients to have access to
      independent and authoritative information” – this doesn’t include lobby groups who have no expertise or understanding of the issue

Leave a reply